• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Consumer Cyclical·122900.KS
Share

iMarketKorea Inc. Stocks

₩ 7270Last Updated 21.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

₩ 157.05M

₩ 7270
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

iMarketKorea Inc. is a prominent provider of industrial material distribution services, operating both domestically in South Korea and internationally. Its comprehensive service offerings encompass procurement solutions like purchasing agency, consulting, and business-to-business auction platforms. Additionally, it manages diverse sourcing initiatives, leveraging local, export, and global supply chains. The company also facilitates the distribution of a broad spectrum of products, including industrial goods, building materials, IT hardware, pharmaceuticals, and medical provisions. Complementing these, it operates an e-commerce platform. Established in 2000, iMarketKorea Inc. is headquartered in Seoul, South Korea.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.07.2026 21:08

Novo has filed a lawsuit against its competitor, Eli Lilly, over advertisements for weight-loss drugs

21.07.2026 20:21

Jefferies Forecasts Meta to Generate Billions in Revenue from AI Glasses. What Will Happen to the Stock?

21.07.2026 19:15

Stock of depression drugmaker Neuronetics adds 25% after BTIG initiation at 'buy'

21.07.2026 18:54

The U.S. president may impose new tariffs on dozens of countries this week — FT

21.07.2026 18:18

Chinese AI models have caught up with their American counterparts. Will Beijing now restrict access to them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026